Immune Checkpoint Inhibitor-Associated Systemic Sclerosis in the Treatment of a Small Cell Lung Cancer Patient with Durvalumab: A Case Report
De-Hu Li,Xian-Zhi Xiong
DOI: https://doi.org/10.2147/ccid.s451386
2024-03-18
Clinical Cosmetic and Investigational Dermatology
Abstract:De-Hu Li, Xian-Zhi Xiong Department of Pulmonary and Critical Care Medicine, NHC Key Laboratory of Pulmonary Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China Correspondence: Xian-Zhi Xiong, Email As one of the key cancer treatment measures, immune-checkpoint inhibitors (ICIs) have revolutionized the treatment landscape of various cancers, including malignancies previously thought to be untreatable. Immune checkpoint inhibitors work by targeting the dysfunctional immune system, to enhance cancer-cell killing by CD8-positive T cells. Despite the beneficial effects of ICIs, these treatments are also linked to a novel class of side effects, termed immune-related adverse events (irAEs). Immune-related adverse events can affect multiple organ systems, such as endocrine, neurological, gastroenteric, dermatologic, ocular, hepatic, renal, and rheumatic ones. While variable in severity, irAEs can be associated with significant morbidity, mortality, cessation of ICI treatment and can be potentially life-threatening sometimes. Among varieties of irAEs, dermatological manifestations are frequently reported, since they can be easily observed. Here, we present a case of a 74-year-old patient with widespread fibrosis of skin, eventually diagnosed as diffuse cutaneous systemic sclerosis after the treatment with durvalumab for small cell lung cancer (SCLC). Prompt recognition and treatment of immune-checkpoint inhibitors-associated systemic sclerosis may help enhance tolerance to ICIs and ensure better performance in treating tumors. Keywords: systemic sclerosis, durvalumab, small cell lung cancer, immune checkpoint inhibitors, immune-related adverse events Immune-checkpoint inhibitors (ICIs) have become a crucial component of cancer treatment. 1 Starting with the approval of anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA-4) for advanced-stage melanoma in 2011, immune checkpoint inhibitors (ICIs) have been widely applied in the treatment of a variety of malignancies. 2 Instead of CTLA-4 (ipilimumab), ICIs now also include antibodies against programmed cell death 1 (PD-1; nivolumab, pembrolizumab, cemiplimab, sintilimab, camrelizumab, toripalimab, tislelizumab, zimberelimab, prolgolimab, and dostarlimab) and its ligand (PD-L1; atezolizumab, avelumab, and durvalumab). 3 Immune checkpoints are receptors expressed on immune cells and allow for the dynamic regulation of immunological homeostasis. 1 PD-1 and PD-L1 are expressed on T cells, tumor cells and tumor-infiltrating myeloid cells, respectively. 1 T cell exhaustion is caused by the interaction of these two proteins and is characterized by decreased or missing effector function (cytotoxicity or cytokine production), lack of reactivity to stimuli and altered transcriptional and epigenetic states. 4,5 On the other hand, CTLA-4 is one type of negative immune regulator constitutively expressed on regulatory T (Treg) cells and upregulated on activated T cells. 6 CTLA-4 inhibits T cell activation through various suppressive functions including competition with CD28, regulation of the inhibitory function of Treg cells, such as transendocytosis, and the control of adhesion and motility. 6 However, more and more immune-related adverse effects (irAEs), which are unique and accompanied by a delayed onset and prolonged duration, have been reported as a result of this increased use. 7 IrAEs can occur in any organ system and 2–16 weeks can be the median onset after the start of therapy. 8 Varieties of dermatological manifestations can occur associated with ICIs such as vitiligo, lichenoid dermatitis, psoriasis, bullous pemphigoid, granulomatous diseases, drug rash with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome and Sweet syndrome. 9–11 The anti-PD-1 (34–42%) and anti-PD-L1 monotherapy (−20%) are associated with lower rates of cutaneous adverse events than anti-CTLA-4 monotherapy (44–59%), but combination therapy is linked to the highest incidence (59–72%). 11,12 However, among these dermatological irAEs, systemic sclerosis induced by the treatment of durvalumab in small cell lung cancer (SCLC) patients has not been reported before. Here, we described a case of durvalumab-associated systemic sclerosis in a patient with SCLC after the treatment with durvalumab. A 74-year-old man was admitted to hospital with cough and chest tightness for one month. He complained of a cough with no obvious cause in the past month, which intensified into paroxysms, coughing up pus sputum, accompanied by chest tightness, shortness of breath, dyspnea, hemoptysis, and sometimes blood in the sputum. He had not had autoimmune diseases in the past, and he denied prior f -Abstract Truncated-
dermatology